Human platelet antigen

Human Platelet Antigen (HPA) refers to a group of genetic polymorphisms found on the surface of platelets. These antigens play a significant role in the immune response, particularly in the context of platelet transfusion, pregnancy, and certain autoimmune diseases. The identification and understanding of HPAs are crucial in preventing and managing conditions such as platelet transfusion reactions, neonatal alloimmune thrombocytopenia (NAIT), and post-transfusion purpura (PTP).

Overview

Human Platelet Antigens are polymorphic proteins located on the surface of platelets, which are small blood cells involved in hemostasis and blood clot formation. The genetic variations in HPAs arise from single nucleotide polymorphisms (SNPs) in the genes encoding platelet membrane glycoproteins. These variations can lead to differences in the antigenic properties of platelets among individuals.

Classification

HPAs are classified based on the specific glycoprotein and the nature of the polymorphism. The most commonly referenced HPAs include HPA-1, HPA-2, HPA-3, HPA-4, and HPA-5, among others. Each HPA is further divided into specific alleles, such as HPA-1a and HPA-1b, which differ by a single amino acid. The presence or absence of specific HPAs can influence an individual's susceptibility to certain platelet-related disorders.

Clinical Significance

The clinical significance of HPAs lies in their role in immune-mediated platelet disorders. Incompatibility between HPAs in a donor and recipient can lead to immune responses that destroy transfused platelets, a condition known as alloimmunization. This is a concern in patients requiring repeated platelet transfusions, such as those with chronic thrombocytopenia or undergoing chemotherapy.

Neonatal Alloimmune Thrombocytopenia

NAIT occurs when a pregnant woman forms antibodies against fetal platelets, leading to thrombocytopenia in the newborn. This condition is analogous to Rh disease in erythrocytes but involves platelets. It typically arises when the fetus inherits an HPA from the father that is absent in the mother.

Post-Transfusion Purpura

PTP is a rare but severe condition that occurs after a platelet transfusion. The recipient, usually previously sensitized through pregnancy or transfusion, forms antibodies against a specific HPA found in the transfused platelets, leading to a sudden and profound drop in the patient's own platelet count.

Diagnosis and Management

The diagnosis of HPA-related disorders involves detecting antibodies against specific HPAs, typically through serological testing or genotyping. Management strategies may include the use of HPA-matched platelet transfusions, intravenous immunoglobulin (IVIG), or other immunosuppressive therapies to prevent or treat immune-mediated platelet destruction.

Conclusion

Human Platelet Antigens are critical determinants of immune responses to platelets, with significant implications for transfusion medicine, obstetrics, and the management of autoimmune thrombocytopenia. Advances in genotyping and the availability of HPA-matched platelet products have improved the prognosis for individuals affected by HPA-related disorders.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian